Volume 10 Supplement 2
Proceedings of the 2012 Sino-American Symposium on Clinical and Translational Medicine (SAS-CTM)
Meeting abstracts
Edited by Fan Daiming, Cao Xuetao, Shengli Yang and John I Gallin
Publication of this supplement has been supported by Chinese Academy of Engineering (CAE), Chinese Academy of Medical Sciences, NIH-CC, Global MD Organization, Division of Medical and Health of CAE and Shanghai Consulting and Academic Activities Center for Academicians of CAE.
2012 Sino-American Symposium on Clinical and Translational Medicine (SAS-CTM). Go to conference site.
Shanghai, China27-29 June 2012
Page 1 of 2
-
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A1
-
New infrastructure to support clinical translational research at the US National Institutes of Health: role of the NIH Clinical Center
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A2 -
Developing innovative targeted therapies for China
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A3 -
Rationale for key elements of Sino-American collaboration in clinical research
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A4 -
Clinical and translational medicine in Europe – horizon 2020 and beyond
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A5 -
Advanced cardiovascular imaging: from patients to populations
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A6 -
The somatic genetic architecture of human cancer: heterogeneity and the challenges for translational medicine
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A7 -
Targeting androgen receptor as a new potential therapeutic approach to battle tobacco carcinogens-induced non-small cell lung cancer
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A8 -
Molecular genetic study in hepatocellular carcinoma: microRNA deregulation in multistep hepatocarcinogenesis
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A9 -
Prevention for colorectal cancer: from basic research to clinical study
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A10 -
Translational research to practice for gastric cancer: molecular classification and outcome prediction based on genomic and proteomic profiling
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A11 -
PHC: the future of oncology drug development
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A12 -
Translational medicine research on early detection and early diagnosis of colorectal cancer in China
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A13 -
Understanding hepatotoxicity – from patients to mice to computer
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A14 -
Circulating microRNA, secreted microRNA and exogenous plant microRNA
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A15 -
Susceptible genes of type 2 diabetes and their disease predictive power in Chinese population
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A16 -
Metabolic profiling of human colorectal cancer: a top-down approach to translational cancer research
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A17 -
Systems pharmacology and drug repositioning- an integrated approach to metabolic diseases
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A18 -
Pharmacogenomics in type 2 diabetes management: towards personalized medicine
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A19 -
Hypoxia in obesity - from bench to bedside
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A20 -
Translational research in type 2 diabetes
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A21 -
A grand challenge about multiple metabolic control: health care delivery from tertiary level hospital to primary care health center
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A22 -
Development of targeted biologics for systemic lupus erythematosus
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A23 -
Primary biliary cirrhosis and autoimmunity: molecules and mimics
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A24 -
The emerging importance of autoimmune hepatitis in China
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A25 -
From common origin of life to seeking common path of diseases – a new paradigm of translation
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A26 -
The role of imaging informatics in clinical translational research: perspectives and challenges from a US academic institution
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A27 -
Brain imaging biomarkers for the Alzheimer’s Prevention Initiative
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A28 -
Magnetic resonance imaging for translational and basic life sciences
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A29 -
20 years translation of ultrasonic elastography: technology innovation and clinical applications
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A30 -
Positron emission tomography imaging of amyloid-beta plaque deposition: a decade of translation
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A31 -
Building Biomedical Imaging and Informatics e-Science platform for translational medical research
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A32 -
Thinking about translational medicine and traditional Chinese medicine
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A33 -
Utilizing traditional Chinese for the discovery of efficacious new drugs
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A34 -
Traditional Chinese medicine for irritable bowel syndrome: from classic formula to modern medicine development
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A35 -
Modern research of TCM etiology and pathogenesis theory and translational medicine
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A36 -
Evidence-based quality criteria in research, development and application of Chinese medicines
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A37 -
Current status and considerations on biosimilar in China
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A38 -
A strategic thinking of the scientific system of drug regulatory in China - advancing drug standards of China
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A39 -
US regulatory approaches to chemistry, manufacturing, and controls for botanical drug products
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A40 -
Translational toxicology and exposomics for food safety risk management
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A41 -
The role of corporate-academic research partnerships in bringing novel therapeutics and diagnostics to the market
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A42 -
Approaches in rare diseases and pediatrics across international boundaries
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A43 -
Translational medicine from observation to hypothesis to interpretation
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A44 -
Suboptimal health: a potential preventive instrument for non-communicable disease control and management
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A45 -
The challenge of studying complex diseases undergoing complex treatments: the metastatic cancer model
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A46 -
Cell phone based telemedicine - brief introduction
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A47 -
Monitoring targeted drug delivery: a key cornerstone of precision medicine
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A48 -
A quaternary equation for interdisciplinary medical research (IMR)
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A49 -
Biobanking and microRNA – small but with great dividend
Citation: Journal of Translational Medicine 2012 10(Suppl 2):A50
Follow
Annual Journal Metrics
-
Citation Impact
8.448 - 2-year Impact Factor (2021)
7.547 - 5-year Impact Factor (2021)
1.582 - Source Normalized Impact per Paper (SNIP)
1.570 - SCImago Journal Rank (SJR)Speed
6 days to first decision for all manuscripts (Median)
14 days to first decision for reviewed manuscripts only (Median)Usage
4,243,080 Downloads (2022)
7,409 Altmetric mentions (2021)